Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.

Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P; SAFEHEART Investigators.

J Am Coll Cardiol. 2016 Mar 22;67(11):1278-85. doi: 10.1016/j.jacc.2016.01.008.

2.

Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study.

Fuentes F, Alcala-Diaz JF, Watts GF, Alonso R, Muñiz O, Díaz-Díaz JL, Mata N, Sanchez Muñoz-Torrero JF, Brea Á, Galiana J, Figueras R, Aguado R, Piedecausa M, Cepeda JM, Vidal JI, Rodríguez-Cantalejo F, López-Miranda J, Mata P; SAFEHEART Investigators.

Int J Cardiol. 2015 Dec 15;201:79-84. doi: 10.1016/j.ijcard.2015.07.107. Epub 2015 Aug 5.

PMID:
26296047
3.

Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.

Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, Padró T, Muñiz O, Díaz-Díaz JL, Mauri M, Ordovás JM, Mata P; SAFEHEART Investigators.

J Am Coll Cardiol. 2014 May 20;63(19):1982-9. doi: 10.1016/j.jacc.2014.01.063. Epub 2014 Mar 13.

4.

Cerebral hemodynamics and endothelial function in patients with Fabry disease.

Segura T, Ayo-Martín O, Gómez-Fernandez I, Andrés C, Barba MA, Vivancos J.

BMC Neurol. 2013 Nov 11;13:170. doi: 10.1186/1471-2377-13-170.

5.

[Comparison of patients from a Spanish Registry of Fabry disease in two periods].

Barba Romero MÁ, Rivera Gallego A, Pintos Morell G; Grupo Español de Estudio del FOS.

Med Clin (Barc). 2012 Oct 13;139(9):379-84. doi: 10.1016/j.medcli.2011.11.026. Epub 2012 Jan 21. Spanish.

PMID:
22266083
6.

Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS).

Barba-Romero MÁ, Rivera-Gallego A, Pintos-Morell G; Spanish FOS-Study Group.

Int J Clin Pract. 2011 Aug;65(8):903-10. doi: 10.1111/j.1742-1241.2011.02695.x. Epub 2011 Jun 16.

PMID:
21679285
7.

[Role of cardiac magnetic resonance in cardiac involvement of Fabry disease].

Serra VM, Barba MA, Torrá R, Pérez De Isla L, López M, Calli A, Feltes G, Torras J, Valverde V, Zamorano JL.

Med Clin (Barc). 2010 Sep 4;135(7):300-5. doi: 10.1016/j.medcli.2009.11.044. Epub 2010 Jun 4. Spanish.

PMID:
20605170
8.

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT; Fabry Outcome Survey investigators.

Lancet. 2009 Dec 12;374(9706):1986-96. doi: 10.1016/S0140-6736(09)61493-8. Erratum in: Lancet. 2010 Jan 16;375(9710):200.

PMID:
19959221
9.

Kidney transplantation in patients with Fabry disease.

Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder-Plassmann G; European FOS Investigators Group.

Transpl Int. 2009 Apr;22(4):475-81. doi: 10.1111/j.1432-2277.2008.00824.x. Epub 2009 Jan 22.

10.

Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy.

Toro R, Perez-Isla L, Doxastaquis G, Barba MA, Gallego AR, Pintos G, Barbados FJ, Mangas A, Zamorano JL.

Int J Cardiol. 2009 Feb 6;132(1):38-44. doi: 10.1016/j.ijcard.2008.04.075. Epub 2008 Aug 8.

PMID:
18691784
11.

Prospective study of methodological issues in intracranial pressure monitoring in patients with hydrocephalus.

Poca MA, Sahuquillo J, Barba MA, Añez JD, Arikan F.

J Neurosurg. 2004 Feb;100(2):260-5.

PMID:
15086233
12.

[Septic arthritis by Streptococcus equisimilis in a patient allergic to beta-lactam antibiotics and aminoglycosides].

Fernández T, Blas JJ, Escribano E, Yeste F, Barba MA, Crespo MD.

Enferm Infecc Microbiol Clin. 1999 Oct;17(8):418-9. Spanish. No abstract available.

PMID:
10563096
13.

[Hepatic fascioliasis resistant to bithionol treatment but responsive to triclabendazole].

Medrano F, de Tomás E, Barba MA, Alamillo A, Ferreras P.

Enferm Infecc Microbiol Clin. 1999 Aug-Sep;17(7):371-2. Spanish. No abstract available.

PMID:
10535200
14.

Pneumopericardium without subcutaneous emphysema, pneumomediastinum, or pneumothorax after laparoscopy.

Barba MA, Saez L, García-Molinero MJ, Aguilera M.

Gastrointest Endosc. 1993 Sep-Oct;39(5):740. No abstract available.

PMID:
8224717
15.

[Hepatopathy from cyanamide. Presentation of a new case].

Fernández-Fúnez A, Moreno M, Barba MA, Beato JL, Puras A.

An Med Interna. 1992 Aug;9(8):411. Spanish. No abstract available.

PMID:
1391567
16.

Affect levels in a company of basic trainees.

Datel WE, Engle EO, Barba MA.

Psychol Rep. 1966 Dec;19(3):903-9. No abstract available.

PMID:
5981101

Supplemental Content

Loading ...
Support Center